Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Anelixis Therapeutics is a clinical stage development company located in Cambridge, Massachusetts. Anelixis has a portfolio of antibodies blocking CD40L activity. Anelixis is developing its lead compound, AT-1501, in Amyotrophic Lateral Sclerosis, organ and cellular transplantation, and autoimmunity. Anelixis Therapeutics was formed in 2013 and is a for-profit subsidiary of ALS Therapy Development Institute (ALSTDI, www.als.n...
Anelixis Therapeutics is a clinical stage development company located in Cambridge, Massachusetts. Anelixis has a portfolio of antibodies blocking CD40L activity. Anelixis is developing its lead compound, AT-1501, in Amyotrophic Lateral Sclerosis, organ and cellular transplantation, and autoimmunity. Anelixis Therapeutics was formed in 2013 and is a for-profit subsidiary of ALS Therapy Development Institute (ALSTDI, www.als.net), a nonprofit biotechnology organization dedicated to developing effective treatments for ALS.

List your booth number for exhibitions, ask us